New Data on Breast Imaging Using Cardiolite® to be Presented at ASCO Breast Cancer Symposium
N. Billerica, MASSACHUSETTS (September 5, 2008) - Lantheus Medical Imaging, a worldwide leader in diagnostic imaging, announced today that the company’s leading imaging agent, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) will be featured in a new study on molecular breast imaging being presented on Sunday, September 7, 2008, at 7:00am -12:00pm (EDT) as part of the poster sessions (abstract #68) at the American Society of Clinical Oncology’s 2008 Breast Cancer Symposium in Washington, DC.
“This promising new study on molecular breast imaging provides encouraging data for millions of women and families who are impacted by breast cancer and sheds light on potential new diagnostic approaches for finding tumors in women who have dense breast tissue, which can confound mammograms,” stated Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. “We are proud to supply the imaging agent for this important clinical effort. Breast cancer is a devastating disease and we recognize how important and valuable early detection is for women.”
About Cardiolite® Breast Imaging
This imaging test is used to assist in the evaluation of breast lesions in some women who have had an abnormal mammogram, or who have a palpable breast mass. The imaging test is not used for screening, or in place of a mammogram. In this test, a woman receives an injection of a small amount of a short-lived radioactive substance called Cardiolite®, which is taken up by cancer cells, and a gamma camera is used to obtain images of the breasts.
Cardiolite®, formerly marketed as Miraluma™ for the breast cancer imaging indication, is FDA-approved for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Cardiolite® is not indicated for breast cancer screening, or to confirm the presence or absence of a malignancy, and is not an alternative to biopsy. Cardiolite® is also indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.
Diagnostic sensitivity is decreased for lesions less than 1cm. Cardiolite® has been rarely associated with acute severe allergic events of angioedema and urticaria. The most frequently reported adverse events include headache, breast pain (mostly associated with biopsy/surgery), nausea, and abnormal taste and smell.
About Lantheus Medical ImagingLantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for the past 50 years, is committed to elevating and investing in the field of diagnostic imaging. The company’s proven success in discovering, developing and marketing innovative medical imaging agents provides an unparalleled platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. The company is home to leading diagnostic imaging brands, including Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, and TechneLite® (Technetium Tc99m Generator) and has nearly 700 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia. For more information, visit www.lantheus.com.